At #ESHG2026, we're showcasing how our sequencing and multiomics solutions are helping researchers unlock deeper biological insights. From discovery to impact, we’re advancing genomics to improve understanding of human health and disease. Visit Booth 328, June 13–15, and join our corporate sessions exploring the path from insight to impact: emea.illumina.com/events/con…

🎥At #EACR2026, integrated multiomics is transforming cancer research. With the launch of StrataMap Spatial, we’re expanding what’s possible with discovery at single‑cell resolution. Join the conversation at Booth 80 in Budapest to see how genomic, proteomic, and spatial data come together to unlock deeper insight. Plus, stop by our AI Photo Booth to join the league of genomics superheroes. Don’t miss our @illumina symposium tomorrow for a closer look at how these approaches are shaping the future of cancer research: emea.illumina.com/events/con…

Introducing StrataMap Spatial, a powerful end-to-end whole-transcriptome solution with unmatched breadth of coverage and resolution StrataMap Spatial expands researchers’ ability to understand the structure and function of tissues, study tumor microenvironments, and identify novel drug targets for precision medicine. (1/2) #EACR2026

What, exactly, is multiomics?" You might be asking how will it impact the future of research and medicine. To answer that, today we are introducing our Multiomics Explained series🧬 This will help elucidate the hottest topic in the industry since “genomics,” enabling you to understand how researchers are enhancing their studies with our innovative solutions that enable an entire ecosystem of insights. Explore the first installment 🔗 : illumina.com/company/news-ce…

“The most exciting time in the space of oncology.” At #ASCO26 we shared more about our recently announced whole-genome based molecular residual disease (MRD) research ecosystem –– changing the game for detection of cancer recurrence. As a distributed solution for MRD research, this technology will enable tumor fingerprinting and ctDNA tracking faster. Learn more: illumina.com/company/news-ce… #genomics #multiomics

Watch our first demo of the recently launched fireflyGO automation solution with the MiSeq i100 at #ASCO26 — an on-demand application library and on-board thermocycler means end-to-end library prep for Pillar oncoReveal panels has never been easier. 📍See fireflyGO in action at Booth #33106 and learn more on this announcement here: illumina.com/company/news-ce… @SPTLabtech @ASCO #genomics #multiomics

Illumina and @SPTLabtech are launching the new fireflyGO automation system—a benchtop solution designed to simplify and accelerate targeted oncology workflows. By integrating automated library preparation and liquid handling with the MiSeq i100 Series, fireflyGO helps laboratories: ✅ Reduce hands-on time and manual touchpoints ✅ Improve reproducibility and reliability ✅ Streamline workflows and scale operations ✅ Increase access to genomic testing in oncology The system also supports a growing menu of Pillar Biosciences oncoReveal panels, expanding flexibility for researchers working across solid tumors, hematologic malignancies, and lymphoid conditions. Together, these innovations reflect our ongoing commitment to making next-generation sequencing more accessible, efficient, and impactful—helping accelerate the adoption of genomics in cancer research and care. 📍See fireflyGO in action at the ASCO Annual Meeting (Booth #33106) in Chicago, May 29–June 2, and learn more on this announcement here: illumina.com/company/news-ce… #ASCO26

Molecular residual disease research is changing the game for detection of cancer recurrence. Now, @illumina is developing a new solution that will bring these genomic breakthroughs to more labs around the world. As a distributed whole-genome sequencing solution for MRD research — this technology will enable tumor fingerprinting and ctDNA tracking faster and for more patients. By combining whole-genome breadth with high analytical sensitivity and the power of DRAGEN, it’s designed to detect true tumor signal with precision. Learn more: illumina.com/company/news-ce… #ASCO26

At #ASCO26, we’re showcasing how genomic solutions are ushering in a new era of precision oncology. Join us at booth 33106 to see how Illumina is accelerating progress across the cancer continuum. Discover more: illumina.com/events/conferen…

🧬@Illumina is redefining whole-genome sequencing, bringing the accuracy and ease of short-read sequencing to comprehensive, genome-wide insight. Running on the NovaSeq X with no additional equipment required, TruPath™ expands access to whole-genome sequencing and reveals historically dark regions of the genome for innovators around the world. Learn more 🔗: illumina.com/products/by-bra… #genomics #multiomics

AI-driven drug discovery requires data at scale. The Billion Cell Atlas offers an unparalleled resource built to train next-gen AI models for precision medicine and drug target identification. Dive deeper with Kyle Farh, VP & Distinguished Scientist at Illumina: illumina.com/areas-of-intere…

🎥 Just how easy is TruPath™ Genome? We sent Illumina’s Chief Medical Officer Eric Green back to the bench to try it for himself. At @illumina Lab Services, Dr. Green rose to the challenge—sharing a few laughs along the way—to demonstrate the unprecedented simplicity of a product that unlocks a whole new standard for genomic insights. Learn more about TruPath™ Genome: illumina.com/products/by-bra… #genomics #multiomics

We’re announcing the Illumina 5-Base Solution for Cancer Research Grant Contest. The contest is elevating epigenetic approaches to oncology research, giving awardees access to @Illumina’s simultaneous genetic and methylation solution, 5-base. We'll be reviewing grant project proposals through June 26, and the grant winner will receive Illumina 5-Base DNA Prep or Illumina 5-Base DNA Prep with Enrichment kits and core consumables to cover 1000 samples. Learn more about eligibility and how to apply 🔗 👇 illumina.com/techniques/sequ… #AACR26 #multiomics #genomics

📸 We kicked off #AACR26 at @illumina HQ with healthcare researchers, laboratory professionals, and oncology pioneers exploring how AI-powered informatics and multiomics are redefining cancer discovery. Attendees got an under-the-hood look at our roadmap, a real-world view on scaling multiomics, and perspectives from Illumina leaders. We shared how integrated oncology and multiomic workflows are pushing the boundaries of translational research and drug discovery. At #AACR26 this weekend? Stop by Booth 4727 to continue the conversation and learn more about all our oncology and multiomic research products: illumina.com/events/conferen… #genomics #multiomics

A team of scientists at @FulgentGenetics is on a mission to improve the diagnostic journey for rare disease patients. Now, they’re diving deep into the genetic drivers of disease with help from @illumina's TruPath™ Genome. Fulgent chief scientific officer Harry Gao, PhD, said: “Time to diagnosis is everything. For genetic disease research and testing, we need speed as well as exceptionally high accuracy in some of the most difficult-to-find variants. Our FulGenome whole genome analysis looks at SNVs, CNVs, genome-wide deletions and duplications, mitochondrial variants, and repeat expansions across 20,000 genes, all in a single report. TruPath™ Genome adds long-range insights where short-read sequencing has traditionally fallen short: complex structural variants, repeat expansions, difficult-to-map regions, and phasing without parental samples, so we can connect the genetic dots faster, and with greater confidence." The whole philosophy behind Fulgent's mission is that a rare disease patient shouldn't have to run a gauntlet of sequential tests to get an answer. Fewer tests. More answers. Less odyssey. Learn more about TruPath™ here: illumina.com/products/by-bra… For Research Use Only. Not for use in diagnostic procedures. #multiomics #genomics

When you see how easy it is to use, there’s no going back: TruPath™ Genome customers are harnessing an amazingly simple workflow to access even some of the most challenging regions of the genome. Learn more about how this simple workflow unlocks more complete genomic insights—with never-before-seen ease, at the lowest end-to-end cost 🔗: illumina.com/products/by-bra… #genomics #multiomics

📰 @GENbio: @Illumina spatial technology is helping customers uncover biomarkers within the microenvironment of a tumor that could lead to better diagnostics and precision therapy. Pratheesh Sathyan, PhD, head of AMR oncology, and Darren Segale, PhD, senior director of scientific research, spoke to GEN about the future of spatial in rare cancers. Read more below 👇genengnews.com/topics/cancer…

In a head-to-head comparison of whole genome sequencing, we found that Illumina’s NovaSeq X and DRAGEN outperformed Complete Genomics/MGI's DNBSEQ-T7 and MegaBOLT. The evaluation found that the Illumina solution:  📉 Results in 8-12× fewer SNV and indel errors  📈 Maintains higher coverage in challenging genomic regions 🎯 Provides more insights into genes relevant to clinical research  Read the full analysis here: illumina.com/science/genomic… #genomics

28 years ago, he drove across the country to join @illumina as employee #4. Today he leads the innovation engine driving the future of sequencing. CTO Steven Barnard kicks off our new video podcast. In “The Sequence” episode 1, Steve sits down with VP and Head of Global Strategic Accounts Ashley Van Zeeland and dives into: 🔶 The early days of innovation at a little-known startup 🔶 Delivering on the “catch 22” customers face between scientific questions and the technology they need to answer them 🔶 The culture of innovation behind the latest breakthroughs in sequencing 🔶 How TruPath™ Genome is already driving incredible insights in rare disease 🔶 Why we didn’t roll out a new “box” at AGBT this year Watch the full episode here: illumina.com/company/news-ce… #genomics #multiomics

Progress in precision cancer care depends on access. We're expanding our collaboration with @Labcorp to broaden access to advanced genomic testing—bringing it closer to where patients receive care. Learn more: bit.ly/4bQbLUQ